Last reviewed · How we verify
Ivonescimab, docetaxel
Ivonescimab is a PD-L1/CTLA-4 bispecific antibody that blocks two immune checkpoints simultaneously, while docetaxel is a microtubule-stabilizing chemotherapy agent, together enhancing anti-tumor immunity and direct cytotoxic effects.
Ivonescimab is a PD-L1/CTLA-4 bispecific antibody that blocks two immune checkpoints simultaneously, while docetaxel is a microtubule-stabilizing chemotherapy agent, together enhancing anti-tumor immunity and direct cytotoxic effects. Used for Non-small cell lung cancer (Phase 3), Other solid tumors (investigational).
At a glance
| Generic name | Ivonescimab, docetaxel |
|---|---|
| Also known as | AK112, docetaxel |
| Sponsor | Akeso |
| Drug class | PD-L1/CTLA-4 bispecific antibody + taxane chemotherapy |
| Target | PD-L1, CTLA-4 (ivonescimab); β-tubulin (docetaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ivonescimab simultaneously engages PD-L1 and CTLA-4 on immune cells, removing dual inhibitory signals and amplifying T-cell activation and proliferation. Docetaxel stabilizes microtubules to disrupt cell division, causing direct tumor cell death. The combination leverages both checkpoint immunotherapy and chemotherapy to target cancer through complementary mechanisms.
Approved indications
- Non-small cell lung cancer (Phase 3)
- Other solid tumors (investigational)
Common side effects
- Neutropenia
- Anemia
- Fatigue
- Nausea/vomiting
- Immune-related adverse events (irAEs)
- Peripheral neuropathy
Key clinical trials
- ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) (PHASE2)
- Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer (PHASE2)
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (PHASE2)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (PHASE2)
- Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） (PHASE2, PHASE3)
- Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer (PHASE3)
- Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |